NEW YORK: The wrenching sell-off in US high-growth technology and biotech shares could leave investors braced for more than a minor pullback when earnings pick up speed next week.
First-quarter earnings estimates have fallen sharply as many companies have blamed the brutal winter for weak outlooks.
